RecruitingNCT02432625
Connective Tissue
Osteogenesis imperfecta type 5
1
studies recruiting now
as of 7 Sept 2026
1
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
4 May 2015
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Osteogenesis imperfecta type 5 studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Osteogenesis imperfecta type 5 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Osteogenesis imperfecta type 5
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (IFITM5).
Treatments being studied
1 approved treatment and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Teriparatide (Bonsity)
Phase 3Denosumab (Jubbonti)
Phase 3Risedronate Sodium (Actonel)
Phase 3Setrusumab
Phase 3Pamidronate Disodium (Aredia)
Phase 3Somatropin (Genotropin)
Phase 3Zoledronic Acid (Aclasta)
Phase 1Busulfan (Busilvex)
Phase 1Romosozumab (Evenity)
+ 4 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).